Tags

Type your tag names separated by a space and hit enter

Comparison of quantitative cytomegalovirus real-time PCR in whole blood and pp65 antigenemia assay: clinical utility of CMV real-time PCR in hematopoietic stem cell transplant recipients.
J Korean Med Sci. 2009 Aug; 24(4):571-8.JK

Abstract

Successful preemptive therapy for cytomegalovirus (CMV) infection in transplant patients depends on the availability of sensitive, specific, and timely diagnostic tests for CMV infection. Although the pp65 antigenemia assay has been widely used for this purpose, real-time quantification of CMV DNA has recently been recognized as an alternative diagnostic approach. However, the guidelines for antiviral therapy based on real-time quantitative polymerase chain reaction (RQ-PCR) have yet to be established. From November 2004 to March 2005, a total of 555 whole blood samples from 131 hematopoietic stem cell transplant (HSCT) recipients were prospectively collected. RQ-PCR was conducted using an Artus CMV LC PCR kit (QIAGEN). Both qualitative and quantitative correlations were drawn between the two methods. Exposure to the antiviral agent influenced the results of the two assays. Additionally, the discrepancy was observed at low levels of antigenemia and CMV DNA load. Via ROC curve analysis, the tentative cutoff value for preemptive therapy was determined to be approximately 2x10(4) copies/mL (sensitivity, 80.0%; specificity, 50.0%) in the high risk patients, and approximately 3x10(4) copies/mL (sensitivity, 90.0%; specificity, 70.0%) in the patients at low risk for CMV disease. Further study to validate the optimal cutoff value for the initiation of preemptive therapy is currently underway.

Authors+Show Affiliations

Department of Internal Medicine, The Catholic Hemopoietic Stem Cell Transplantation Center, College of Medicine, The Catholic University of Korea, Seoul, Korea.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19654935

Citation

Choi, Su-Mi, et al. "Comparison of Quantitative Cytomegalovirus Real-time PCR in Whole Blood and Pp65 Antigenemia Assay: Clinical Utility of CMV Real-time PCR in Hematopoietic Stem Cell Transplant Recipients." Journal of Korean Medical Science, vol. 24, no. 4, 2009, pp. 571-8.
Choi SM, Lee DG, Lim J, et al. Comparison of quantitative cytomegalovirus real-time PCR in whole blood and pp65 antigenemia assay: clinical utility of CMV real-time PCR in hematopoietic stem cell transplant recipients. J Korean Med Sci. 2009;24(4):571-8.
Choi, S. M., Lee, D. G., Lim, J., Park, S. H., Choi, J. H., Yoo, J. H., Lee, J. W., Kim, Y., Han, K., Min, W. S., Shin, W. S., & Kim, C. C. (2009). Comparison of quantitative cytomegalovirus real-time PCR in whole blood and pp65 antigenemia assay: clinical utility of CMV real-time PCR in hematopoietic stem cell transplant recipients. Journal of Korean Medical Science, 24(4), 571-8. https://doi.org/10.3346/jkms.2009.24.4.571
Choi SM, et al. Comparison of Quantitative Cytomegalovirus Real-time PCR in Whole Blood and Pp65 Antigenemia Assay: Clinical Utility of CMV Real-time PCR in Hematopoietic Stem Cell Transplant Recipients. J Korean Med Sci. 2009;24(4):571-8. PubMed PMID: 19654935.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparison of quantitative cytomegalovirus real-time PCR in whole blood and pp65 antigenemia assay: clinical utility of CMV real-time PCR in hematopoietic stem cell transplant recipients. AU - Choi,Su-Mi, AU - Lee,Dong-Gun, AU - Lim,Jihyang, AU - Park,Sun Hee, AU - Choi,Jung-Hyun, AU - Yoo,Jin-Hong, AU - Lee,Jong-Wook, AU - Kim,Yonggoo, AU - Han,Kyungja, AU - Min,Woo-Sung, AU - Shin,Wan-Shik, AU - Kim,Chun-Choo, Y1 - 2009/07/29/ PY - 2008/05/30/received PY - 2008/08/27/accepted PY - 2009/8/6/entrez PY - 2009/8/6/pubmed PY - 2009/11/7/medline KW - Antigenemia KW - Cutoff KW - Cytomegalovirus KW - Hematopoietic Stem Cell Transplantation KW - Real-time PCR SP - 571 EP - 8 JF - Journal of Korean medical science JO - J Korean Med Sci VL - 24 IS - 4 N2 - Successful preemptive therapy for cytomegalovirus (CMV) infection in transplant patients depends on the availability of sensitive, specific, and timely diagnostic tests for CMV infection. Although the pp65 antigenemia assay has been widely used for this purpose, real-time quantification of CMV DNA has recently been recognized as an alternative diagnostic approach. However, the guidelines for antiviral therapy based on real-time quantitative polymerase chain reaction (RQ-PCR) have yet to be established. From November 2004 to March 2005, a total of 555 whole blood samples from 131 hematopoietic stem cell transplant (HSCT) recipients were prospectively collected. RQ-PCR was conducted using an Artus CMV LC PCR kit (QIAGEN). Both qualitative and quantitative correlations were drawn between the two methods. Exposure to the antiviral agent influenced the results of the two assays. Additionally, the discrepancy was observed at low levels of antigenemia and CMV DNA load. Via ROC curve analysis, the tentative cutoff value for preemptive therapy was determined to be approximately 2x10(4) copies/mL (sensitivity, 80.0%; specificity, 50.0%) in the high risk patients, and approximately 3x10(4) copies/mL (sensitivity, 90.0%; specificity, 70.0%) in the patients at low risk for CMV disease. Further study to validate the optimal cutoff value for the initiation of preemptive therapy is currently underway. SN - 1598-6357 UR - https://www.unboundmedicine.com/medline/citation/19654935/Comparison_of_quantitative_cytomegalovirus_real_time_PCR_in_whole_blood_and_pp65_antigenemia_assay:_clinical_utility_of_CMV_real_time_PCR_in_hematopoietic_stem_cell_transplant_recipients_ L2 - https://jkms.org/DOIx.php?id=10.3346/jkms.2009.24.4.571 DB - PRIME DP - Unbound Medicine ER -